Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Filings indexed 444 across all filing types
Latest filing 2025-10-01 Major Shareholding Noti…
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' (TR-1 form) filed via RNS. It details a change in shareholding by Pentwater Capital Management LP in Renalytix PLC, specifically crossing a reporting threshold. This fits the definition of a Major Shareholding Notification (MRQ).
2025-10-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' filed by Pentwater Capital Management LP regarding their interest in Renalytix PLC. It explicitly details the crossing of shareholding thresholds, including both direct equity and financial instruments (swaps). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-10-01 English
CE Mark application submission
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces a specific corporate development: the submission of an application for CE Mark certification for the company's diagnostic test. It does not fit into specific categories like financial reports, board changes, or dividend announcements. As it is a general regulatory announcement regarding company operations, it falls under the RNS category.
2025-10-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. This is a regulatory requirement in the UK for shareholders to disclose when their voting rights in a company cross certain thresholds. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2025-09-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' filed by Renalytix PLC. It explicitly details a change in share ownership by Pentwater Capital Management LP, crossing a reporting threshold. This is a classic 'Major Shareholding Notification' (TR-1 form in the UK), which corresponds to the MRQ filing category.
2025-09-29 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in shareholding percentage by Unicorn Asset Management Limited in Renalytix plc, crossing a regulatory threshold. This is a standard regulatory disclosure for major shareholding notifications, which corresponds to the MRQ filing category.
2025-09-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.